Answers are grounded in this paper and cite their sources.
Methotrexate (MTX) is a primary therapy for juvenile idiopathic arthritis (JIA) but carries a risk of hepatotoxicity that routine liver enzymes may not detect. We evaluated liver fibrosis and steatosis in MTX-treated children with JIA using transient elastography and non-invasive scores (APRI, FIB-4, FAST). This cross-sectional comparative study included 74 children with JIA receiving MTX monotherapy and 79 healthy controls, selected to match age and sex distributions. Body mass index was also assessed to evaluate comparability between the groups. Liver stiffness measurement (LSM), controlled attenuation parameter (CAP), APRI, FIB-4, and FAST were compared, and their relationship with cumulative MTX dose, treatment duration, and disease activity was assessed. Median LSM (4.50 vs. 3.90 kPa; p = 0.007), APRI (0.187 vs. 0.178; p = 0.005), and FAST (0.06 vs. 0.05; p = 0.008) were statistically higher in patients with JIA than in healthy controls, whereas CAP values did not differ significantly. Using pediatric thresholds, 21/74 patients (28.4%) and 11/79 controls (13.9%) exceeded 5 kPa, above which any fibrosis cannot be excluded ( p = 0.031); at the 7 kPa threshold for significant fibrosis the groups were identical (2.7% vs. 2.5%; p = 1.000). In age-stratified analyses, LSM (4.50 vs. 3.55 kPa; p = 0.011), APRI (0.267 vs. 0.191; p = 0.001), and FAST (0.10 vs. 0.06; p = 0.005) were significantly higher in children aged 2–12 years with JIA than in healthy controls, whereas no significant differences were observed among adolescents older than 12 years. Neither cumulative MTX dose nor treatment duration was associated with liver stiffness, and FIB-4 was paradoxically higher in controls, reflecting its age dependence. In MTX-treated children with JIA, higher liver stiffness was confined to the uncertain 5–7 kPa range and was not associated with cumulative MTX exposure or treatment duration in this cohort, with no difference at the significant-fibrosis threshold. Non-invasive scores performed inconsistently, underscoring the need for age-adjusted, pediatric-specific reference values before they are used to guide hepatic monitoring.
No takes yet. Share an insight, caveat, or question.
Aksu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: